Brief: Eagle Pharmaceuticals Inc- Co Entered Into The Third Amended And Restated Credit Agreement
03/11/2022 10:23
Nov 3 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS INC- ON NOVEMBER 1, 2022 CO ENTERED
INTO
THE THIRD AMENDED AND RESTATED CREDIT AGREEMENT
* EAGLE PHARMACEUTICALS INC- AMENDED CREDIT AGREEMENT
PROVIDES
FOR A THREE-YEAR $100 MILLION REVOLVING CREDIT FACILITY
* EAGLE PHARMACEUTICALS INC- ON AMENDMENT DATE, CO BORROWED
$15
MILLION UNDER THE REVOLVING CREDIT FACILITY AND $50 MILLION
UNDER THE TERM LOAN FACILITY
* EAGLE PHARMACEUTICALS INC- REVOLVING CREDIT FACILITY AND
THE
TERM LOAN FACILITY EACH MATURE ON OCTOBER 31, 2025
Source text for Eikon: ID:
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq